drugset / Trial / NCT04327661
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel
Timeline
- Start
- 2021-11-15
- Primary completion
- 2023-04-01
- Completion
- 2023-04-12
Publications
- Nguyen T, Willett KC, Daly LR, Junker J, Andreescu O, Dima L. Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness. Am J Ther. 2026 Jul-Aug 01;33(4):e324-e328. doi: 10.1097/MJT.0000000000002147. Epub 2026 May 14.
- Polymeropoulos VM, Kiely L, Bushman ML, Sutherland EB, Goldberg AR, Pham AX, Miller CR, Mourad R, Davis TR, Pham NV, Morgan DB, Giles AK, Xiao C, Polymeropoulos CM, Birznieks G, Polymeropoulos MH. Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study. Front Neurol. 2025 Mar 4;16:1550670. doi: 10.3389/fneur.2025.1550670. eCollection 2025.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tradipitant | Small molecule | 85 mg | Oral |
| Subject | Tradipitant | Small molecule | 170 mg | Oral |